Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Leon-Nanodrugs GmbH is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 4 distinct examiners and several distinct art units, showing a high degree of diversification in the examination process. This ratio of actions to examiners means that every pending application is being reviewed by a unique individual.
LIPPERT, JOHN WILLIAM is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. Since each of the 4 pending actions is assigned to a unique examiner, the company must manage multiple distinct prosecution tracks simultaneously. This lack of overlap prevents the applicant from using a single examiner's feedback to inform the strategy for other applications in the portfolio.
The involvement of 4 distinct art units indicates that the company's nanodrug innovations are being classified into several different pharmaceutical and biotechnological categories. This requires a broad understanding of the various examination standards across these units. With 4 pending office actions and 4 distinct examiners, the prosecution effort is fragmented, requiring coordination to maintain consistency across the entire portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SORKIN, DAVID L | 1 | 67.4% | +12.8% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
| HOLT, ANDRIAE M | 1 | 49.3% | +22.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17595393 | METHOD FOR PRODUCING NANOPARTICLES | HOLT, ANDRIAE M | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17595393 | METHOD FOR PRODUCING NANOPARTICLES | HOLT, ANDRIAE M | 5d |
| 17999851 | METHOD FOR PRODUCING A LIPOSOME DISPERSION | ATKINSON, JOSHUA ALEXANDER | 28d |
| 18042460 | JET IMPINGEMENT REACTOR | SORKIN, DAVID L | — |
| Art Unit | Apps |
|---|---|
| 1774 | 1 |
| 1612 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18042460 | JET IMPINGEMENT REACTOR | SORKIN, DAVID L | 1774 | §103 | Non-Final OA | — | Pending | Feb 22, 2023 |
| 17999851 | METHOD FOR PRODUCING A LIPOSOME DISPERSION | ATKINSON, JOSHUA ALEXANDER | 1612 | §103DP | Final Rejection | 28d | Pending | Nov 24, 2022 |
| 17595393 | METHOD FOR PRODUCING NANOPARTICLES | HOLT, ANDRIAE M | 1614 | §103§112 | Final Rejection | 5d | Pending | Nov 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial